Investigational Drug Details
| Drug ID: | D241 |
| Drug Name: | Nidufexor |
| Synonyms: | LMB763 |
| Type: | Chemical drug |
| DrugBank ID: | DB16255 |
| DrugBank Description: | Nidufexor is under investigation in clinical trial NCT03804879 (Safety, Tolerability and Efficacy of LMB763 in Patients With Diabetic Nephropathy). |
| PubChem ID: | 118063735 |
| CasNo: | 1773489-72-7 |
| Repositioning for NAFLD: | No |
| SMILES: | Cn1c2c(c(n1)C(=O)N(Cc1ccc(cc1)C(=O)O)Cc1ccccc1)COc1c2cc(cc1)Cl |
| Structure: |
|
| InChiKey: | JYTIXGYXBIBOMN-UHFFFAOYSA-N |
| Molecular Weight: | 487.943 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | FXR modulator |
| Therapeutic Category: | Enhance lipid metabolism |
| Clinical Trial Progress: | Phase 2 terminated (NCT02913105) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A03845 | 33849361 | Expert Opin Drug Discov | The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease. | Details |
| A07297 | 32552182 | Expert Opin Investig Drugs | Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). | Details |
| A08915 | 31940200 | J Med Chem | Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. | Details |